Mostrando 3 resultados de: 3
Filtros aplicados
Área temáticas
Enfermedades(2)
Farmacología y terapéutica(2)
Gestión y servicios auxiliares(1)
Medicina y salud(1)
Problemas sociales y servicios a grupos(1)
Origen
scopus(3)
Atherogenic dyslipidemia in Latin America: Prevalence, causes and treatment. Consensus
ReviewAbstract: Atherogenic dyslipidemia (DA) is a poorly recognized entity in the current clinical practice guideliPalabras claves:Atherogenic dyslipidemia, Highdensity lipoprotein, Low-density lipoprotein, Practical recommendations, TriglyceridesAutores:Acevedo M., Bryce A., Carrera C., Gómez-Mancebo J.R., Isea-Perez J.E., Lanas F.T., Lorenzatti A.J., Lozada A.F., Machado L., Medina J., Morales E., PATRICIO LOPEZ -JARAMILLO, Pinto X., Pirskorz D., Ponte-Negretti C.I., Wyss-Quintana F.S.Fuentes:googlescopusConsiderations and guidance for the structure, organisation, and operation of cardiometabolic prevention units: A consensus statement of the Inter-American Society of Cardiology
ArticleAbstract: Cardiovascular diseases (CVDs) remain the leading cause of death worldwide, particularly in low- andPalabras claves:Cardiometabolic prevention unit, cardiometabolic risk, Cardiovascular preventionAutores:Barbosa E.C.D., Borrayo G., Cobos L., Gómez-Mancebo J.R., López-Santi R., Lorenzatti A.J., Machado L., PATRICIO LOPEZ -JARAMILLO, Piskorz D.L., Ponte-Negretti C.I., Puente-Barragan A., Ruiz E., Sosa-Liprandi Á., Valdéz O., Wyss F.S.Fuentes:googlescopusCardiovascular efficacy and safety of bococizumab in high-risk patients
ArticleAbstract: BACKGROUND Bococizumab is a humanized monoclonal antibody that inhibits proprotein convertase subtilPalabras claves:Autores:Abbott J.D., Amarenco P., Anderson P., Baultrukonis D., Black H., Blake G., Borer J.S., Brunell R., Buonanno M., Carmena R., Chakrabarti A., Chaudhuri S., Chun H., Civeira F., Colquhoun D., Conde D., Cortada J.B., Curto M., Dan G.A., Dearborn-Tomazos J., Edes I., Epsley C., Evans B., Flather M., Foody J., Frederich R., Frolova M., Furie K.L., Gao R., Gelfand E., Glynn R.J., Goetsch M., Grégoire J., Grobbee D., Hessinger D., Hwang J.J., Jacoby D., Jadbabaie F., Jensen H.K., Johnson M., Jukema J.W., Kahan T., Karpov Y., Kastelein J.J.P., Koenig W., Lee C.W., Leiva Pons J.L., Lorenzatti A.J., Lotan C., Maggioni A.P., Manga P., Masiukiewicz U., McCullough L., McMurray J.J.V., McNamara R., McPherson C., Mellbin L., Miller M., Missault L., Montalescot G., Mosterd A., Mridha K., Murin J., Neaton J., Nicolau J.C., Nissen S.E., Noble S., O’Neill B., Piazza G., Pinto D., Ponikowski P., Powell C., Pride Y., Revkin J., Ridker P.M., Sandra Verónica Falconí Peláez, Sansing L.H., Santos R.D., Savolainen M., Savonitto S., Schiele F.N., Schindler J., Schwartz P.F., Shear C.L., Silverman I.E., Solar M., Soran H., Sritara P., Tarasenko L., Tardif J.C., Tökgozoğlu L., Urina M., Vrablik M., Wang E., Wei C., Welty F., White H.D., Wright R.S., Yunis C., Zannad F.Fuentes:googlescopus